Comparison of mutational profiles and clinical outcomes in patients with acute myeloid leukemia with mutated RUNX1 versus acute myeloid leukemia with myelodysplasia-related changes with mutated RUNX1

References

• Dohner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373:1136–1152.
   PubMed Web of Science ®Google Scholar
• Suguna E, Farhana R, Kanimozhi E, et al. Acute myeloid leukemia: diagnosis and management based on current molecular genetics approach. Chddt. 2018;18(3):199–207.
   Google Scholar
• Scaffidi C, Schmitz I, Krammer PH, et al. The role of c-FLIP in modulation of CD95-induced apoptosis. J Biol Chem. 1999;274(3):1541–1548.
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumors of haematopoietic and lymphoid tissues. Geneva, Switzerland: WHO Press; 2017.
   Google Scholar
• Dohner H, Eslev E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–447.
   PubMed Web of Science ®Google Scholar
• Swiers G, de Bruijn M, Speck NA. Hematopoietic stem cell emergence in the concepts and the role of Runx1. Int J Dev Biol. 2010;54(6–7):1151–1163.
   PubMed Web of Science ®Google Scholar
• Sakurai M, Kunimoto H, Watanabe N, et al. Impaired hematopoietic differentiation of RUNX1-mutated induced pluripotent stem cells derived from FPD/AML patients. Leukemia. 2014;28(12):2344–2354.
   PubMed Web of Science ®Google Scholar
• Mangan JK, Speck NA. RUNX1 mutations in clonal myeloid disorders: from conventional cytogenetics to next generation sequencing, a story 40 years in the making. Crit Rev Oncog. 2011;16(12):77–91.
   PubMedGoogle Scholar
• Imai Y, Kurokawa M, Izutsu K, et al. Mutations of the AML1 gene in myelodysplastic syndrome and their functional implications in leukemogenesis. Blood. 2000;96(9):3154–3160.
   PubMed Web of Science ®Google Scholar
• Gaidzik VI, Bullinger L, Schlenk RF, et al. RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. JCO. 2011;29(10):1364–1372.
   PubMed Web of Science ®Google Scholar
• Harada H, Harada Y, Niimi H, et al. High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia. Blood. 2004;103(6):2316–2324.
   PubMed Web of Science ®Google Scholar
• Osato M. Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia. Oncogene. 2004;23(24):4284–4296.
   PubMed Web of Science ®Google Scholar
• Gaidzik VI, Teleanu V, Papaemmanuil E, for the German-Austrian Acute Myeloid Leukemia Study Group (AMLSG), et al. RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features. Leukemia. 2016;30(11):2282–2282.
   PubMed Web of Science ®Google Scholar
• Lindsley RC, Mar BG, Mazzola E, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015;125(9):1367–1376.
   PubMed Web of Science ®Google Scholar
• Arber DA, et al. WHO classification of tumors of haematopoietic and lymphoid tissues. Geneva, Switzerland: WHO Press; 2017.
   Google Scholar
• Yun S, Sharma R, Chan O, et al. Prognostic significance of MYC oncoprotein expression on survival outcome in patients with acute myeloid leukemia with myelodysplasia related changes (AML-MRC). Leuk Res. 2019;84:106194.
   PubMed Web of Science ®Google Scholar
• Schnittger S, Dicker F, Kern W, et al. RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis. Blood. 2011;117(8):2348–2357.
   PubMed Web of Science ®Google Scholar
• Tang J-L, Hou H-A, Chen C-Y, et al. AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. Blood. 2009;114(26):5352–5361.
   PubMed Web of Science ®Google Scholar
• Haferlach T, Stengel A, Eckstein S, et al. The new provisional WHO entity ‘RUNX1 mutated AML’ shows specific genetics but no prognostic influence of dysplasia. Leukemia. 2016;30(10):2109–2112.
   PubMed Web of Science ®Google Scholar
• Khan M, et al. Clinical outcomes and co-occurring mutations in patients with RUNX1-mutated acute myeloid leukemia. Int J Mol Sci. 2017;18:1–15.
   Web of Science ®Google Scholar
• Mendler JH, Maharry K, Radmacher MD, et al. RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures. JCO. 2012;30(25):3109–3118.
   PubMed Web of Science ®Google Scholar
• Dombret H, Gardin C. An update of current treatments for adult acute myeloid leukemia. Blood. 2016;127(1):53–61.
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Ravandi F, Liu-Dumlao T, et al. Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. Blood. 2012;120:4840–4845.
   PubMed Web of Science ®Google Scholar
• Gupta N, Miller A, Gandhi S, et al. Comparison of epigenetic versus standard induction chemotherapy for newly diagnosed acute myeloid leukemia patients ≥60 years old. Am J Hematol. 2015;90(7):639–646.
   PubMed Web of Science ®Google Scholar
• Lancet JE, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018;36:2684–2692.
   PubMed Web of Science ®Google Scholar
• Yun S, Vincelette ND, Abraham I, et al. Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials. Clin Epigenet. 2016;8(1):68.
   PubMedGoogle Scholar
• Greif PA, Konstandin NP, Metzeler KH, et al. RUNX1 mutations in cytogenetically normal acute myeloid leukemia are associated with a poor prognosis and up-regulation of lymphoid genes. Haematologica. 2012;97(12):1909–1915.
   PubMed Web of Science ®Google Scholar
• Silva FP, Lind A, Brouwer-Mandema G, et al. Trisomy 13 correlates with RUNX1 mutation and increased FLT3 expression in AML-M0 patients. Haematologica. 2007;92(8):1123–1126.
   PubMed Web of Science ®Google Scholar
• Chen C-Y, Lin L-I, Tang J-L, et al. RUNX1 gene mutation in primary myelodysplastic syndrome–the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome. Br J Haematol. 2007;139(3):405–414.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network, Ley TJ, Miller C, Ding L, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368:2059–2074.
   PubMed Web of Science ®Google Scholar
• West AH, Godley LA, Churpek JE. Familial myelodysplastic syndrome/acute leukemia syndromes: a review and utility for translational investigations. Ann NY Acad Sci. 2014;1310(1):111–118.
   PubMedGoogle Scholar
• Forman D, Stockton D, Møller H, et al. Cancer prevalence in the UK: results from the EUROPREVAL study. Ann Oncol. 2003;14(4):648–654.
   PubMed Web of Science ®Google Scholar
• Churpek JE, Pyrtel K, Kanchi K-L, et al. Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia. Blood. 2015;126(22):2484–2490.
   PubMed Web of Science ®Google Scholar
• Owen C, Barnett M, Fitzgibbon J. Familial myelodysplasia and acute myeloid leukaemia–a review. Br J Haematol. 2007;140(2):123–132.
   Web of Science ®Google Scholar